Compare ALT & FRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALT | FRA |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.4M | 367.5M |
| IPO Year | 2005 | 2003 |
| Metric | ALT | FRA |
|---|---|---|
| Price | $1.45 | $9.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $16.33 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 167.3K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.06% |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $1.50 | $9.65 |
| 52 Week High | $6.44 | $12.23 |
| Indicator | ALT | FRA |
|---|---|---|
| Relative Strength Index (RSI) | 21.10 | 38.51 |
| Support Level | N/A | $9.65 |
| Resistance Level | $3.35 | $11.20 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 1.26 | 4.60 |
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Blackrock Floating Rate Inc Stra Fd Inc is a closed-end management investment company. Its investment objective is to provide shareholders with high current income and such preservation of capital as is consistent with investment in a diversified, leveraged portfolio consisting of floating rate debt securities and instruments. The Fund seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its managed assets in floating rate debt securities, including floating or variable rate debt securities that pay interest at rates that adjust whenever a specified interest rate changes and/or which reset on predetermined dates (such as the last day of a month or calendar quarter).